Introduction
============

Septic shock is described as a distributive shock, requiring fluid and vasopressor administration \[[@B1]\]. In the recent past, evidence for microcirculatory failure as a motor of organ failure during septic shock has grown. It has been shown that distribution of flow within a tissue is impaired by oxygen shunting \[[@B2],[@B3]\], cell aggregation, thrombosis \[[@B4]\], vaso-constriction \[[@B5]\] and/or tissue edema \[[@B6]\]. In the early phase of septic shock, early goal-directed cardiovascular optimization seems more efficient than the conventional strategy \[[@B7]\]. Despite this strategy, some patients continue to have abnormal microperfusion \[[@B8]\], which has been proposed to be targeted therapeutically with a fluid challenge \[[@B8]\], nitric oxide donors \[[@B9],[@B10]\] or activated protein C \[[@B11],[@B12]\]. Before integrating microperfusion parameters into clinical strategies, a better characterization and understanding of microperfusion abnormalities is needed.

Among the tools available for microperfusion assessment, near-infrared spectroscopy (NIRS) seems promising. It has been shown in different life-threatening conditions that tissue hemoglobin oxygen saturation (StO~2~) characterizes tissue hypoperfusion and effectiveness of therapies in trauma \[[@B13]-[@B17]\], septic shock \[[@B18]-[@B22]\], and other acute systemic inflammatory conditions \[[@B23]\]. The large overlap of StO~2~values between healthy subjects and septic shock patients \[[@B15]-[@B18]\] largely limits the interest of this parameter for individual care. As a consequence, a method to better evaluate the tissue micro-oxygenation in septic shock is needed. In this respect, a vascular occlusion test (VOT) combined with StO~2~measurement has been proposed \[[@B17]-[@B20]\].

Measuring StO~2~with a VOT provides a functional test having several potential determinants. These determinants and their relative impact during septic shock remain to be clarified so they can be interpreted adequately before making decisions. The StO~2~occlusion slope was shown to relate to tissue oxygen consumption \[[@B18],[@B19],[@B24]\], and the StO~2~reperfusion slope was proposed to evaluate tissue flow reperfusion and vascular recruitment \[[@B18],[@B22]\] and was found to be abnormal in septic shock \[[@B20]-[@B22]\]. The purpose of the present study was to quantify the micro-oxygenation parameters in a homogeneous septic shock population controlled for severity, to investigate the relationship of micro-oxygenation and macro-perfusion parameters, to investigate the relationship of NIRS parameters and skin laser Doppler (LD) in the same conditions, and to evaluate the association between micro-oxygenation parameters and outcome.

Materials and methods
=====================

The present single-center study was prospectively conducted in the 21-bed surgical intensive care unit at the tertiary Lariboisière University Hospital, between January 2005 and August 2008. The study was approved by the Ethics Committee of the French Society of Intensive Care (CE-SRLF 07-185) and informed consent was given by patients\' next of kin.

Patients
--------

Forty-three patients suffering from septic shock and with at least one additional organ failure were consecutively enrolled. Septic shock was diagnosed according to the criteria given by the Consensus Conference \[[@B1]\]. Measurements were performed as early as possible within the first 24 hours after starting vasopressor therapy (norepinephrine \>0.05 μg/kg/minute). All septic shock patients were enrolled except those in which monitoring StO~2~on the thenar eminence was not possible (one patient).

All patients were mechanically ventilated and invasively monitored for hemodynamic parameters with arterial and central venous catheters (Vigilance PreSep CEDV(X3820HS); Edwards Lifesciences, Irvine, CA, USA) or pulmonary artery catheters (Swan Ganz CCOmboV CCO/SvO2/CEDV; Edwards Lifesciences), with continuous measurement of central venous oxygen saturation (ScvO~2~) or mixed venous oxygen saturation (SvO~2~), respectively. Cardiac output was also measured, either by the thermodilution technique or by esophageal Doppler (CardioQ ED probe; Deltex, Brighton, UK) \[[@B25]\]. Light sedation and analgesia were provided according to the evaluation of individual needs by the physician in charge (flunitrazepam 1 to 2 mg/hour and fentanyl 50 to 200 μg/hour, propofol 50 mg/hour, or ketamine 50 to 200 mg/hour). Measurements were performed distant from modifications in the sedation protocol (at least 6 hours) or in the cardiovascular support (at least 1 hour). Patients were treated according to written intensive care unit standard management for septic shock, very similar to the Surviving Sepsis Campaign \[[@B26]\]. Additional treatments such as recombinant human activated protein C, hydrocortisone or nitric oxide donors were collegially decided. No interventions were based on measured StO~2~parameters.

For each patient, the following data were collected. Routine laboratory items were measured on the first day of septic shock to calculate the Simplified Acute Physiology Score II \[[@B27]\] and the Sequential Organ Failure Assessment (SOFA) score \[[@B28]\]; repeated for calculation of the SOFA score on days 2 and 3. Macrohemodynamic parameters measured were the heart rate, blood pressure, cardiac output, right atrial pressure, ScvO~2~or SvO~2~(catheter measurement) and peripheral oxygen saturation (SpO~2~) (pulse oximetry Dräger SC 9000, adult disposable oximetry sensor Novadiem 3311-V, Nellcor compatible; Drägerwerk AG & Co. KGaA, Lübeck, Germany). The metabolic parameters of arterial and venous blood gases, arterial lactate, and hemoglobin concentration were also collected on days 1, 2 and 3 and were compared with NIRS-derived parameters. Since SvO~2~was measured either in the superior vena cava (ScvO~2~) or in the pulmonary artery (mixed SvO~2~), we analyzed these data separately and then pooled the data after applying a correction for the ScvO~2~. Five percent was subtracted from the ScvO~2~value, according to previous reports \[[@B29]\]. The day-to-day infusion rates of vasopressors, inotropes, and analgesic and sedative drugs during these 72 hours were also collected.

Tissue hemoglobin oxygen saturation measurements
------------------------------------------------

StO~2~was measured by a tissue spectrometer (InSpectra Model 325; Hutchinson Technology, Hutchinson, MN, USA), which uses reflectance-mode probes to measure scattering light reflected at some distance from where the light is transmitted into the tissue. The maximum depth of the tissue sampled is estimated to equal one-half of the distance between the probe\'s sending and receiving fibers (probe spacing) \[[@B13],[@B30]\], which was 25 mm in the present study. A light-scattering calibrator was used to normalize the tissue spectrometer during system startup and before each measurement. StO~2~measurements were updated every 3.5 seconds \[[@B22]\]. This non-invasive technique measures the saturation ratio of oxygenated and deoxygenated hemoglobin. This ratio includes all vessels (arterioles, capillaries and venules) in the tissue sample volume illuminated by the NIRS sensor. The decision to measure StO~2~at the skeletal muscle of the thenar eminence was based on several factors: this area (hand and thenar eminence) is an important target for vascular reflex adaptation \[[@B31]\], having an earlier and more amplified vascular response than many other tissues \[[@B32],[@B33]\]; there is little signal influence of skin and fat tissue for a 12.5 mm depth of measurement \[[@B13],[@B30]\]; and edema is more limited on this area \[[@B34]\]. The sensor was placed on the side free of an arterial catheter to avoid any potential interference.

StO~2~monitoring continued for 72 hours after enrollment. In addition, a VOT was performed four times per day with a rigorous protocol: after a 5-minute baseline measurement, a sphygmomanometer cuff placed over the brachial artery was rapidly inflated to 300 mmHg and maintained for 3 minutes to achieve stagnant arterial ischemia. The cuff was then abruptly deflated and measurements continued for 5 minutes.

The following parameters were measured or calculated from continuous numerical data stored in the device: after occlusion, the slope for StO~2~decay was calculated from six to nine values and called the occlusion slope; similarly, after abrupt release of the cuff inflation, the reperfusion slope was computed on the basis of three or four StO~2~ascending values. The slopes were calculated using statistical linear adjustment. When the linear correlation coefficient *R*^2^was \>0.90, the slope was considered linear and expressed as a percentage per second (normal values ± standard deviation: occlusion slope, -0.46 ± 0.17%/second; reperfusion slope, 9.82 ± 2.11%/second). This strategy for measurements was repeated on days 1, 2 and 3. At day 1, the worst values for StO~2~and VOT calculated parameters were used in survivors, nonsurvivors, and healthy subjects (n = 15) for comparison and for testing the outcome predictable value. Baseline StO~2~and VOT parameters for healthy volunteers were collected in a semirecumbent position after 10 minutes of rest. Data from days 1, 2, and 3 were pooled for a correlation study between NIRS parameters, macrohemodynamic data, metabolic data and LD data. In addition, baseline StO~2~values were compared with other oxygen saturations and the gradients between StO~2~and SvO~2~and between SpO~2~and StO~2~were computed.

Laser Doppler
-------------

The skin blood flow velocity was measured upstream of the StO~2~probe, on the inner side of the homolateral wrist, using the LD technique. The probe was secured and connected to a dual-channel flowmeter (BLF21D; Transonic Systems, Ithaca, NY, USA). Cutaneous blood flow velocity (1.2 mm deep, in arbitrary tissue perfusion units (TPU)) was continuously measured and recorded as a numerical signal onto a computer with an analog/digital transducer (Biopac Systems MP100; BIOPAC Systems, Inc, Goleta, CA, USA) and with data processing software (Acqknowledge 3.81; BIOPAC Systems, Inc).

The same occlusion test used for StO~2~was applied for LD measurements (Figure [1](#F1){ref-type="fig"}). After baseline data registration, the stop flow (VOT) and the post-ischemic reperfusion flow were registered. As shown in Figure [1](#F1){ref-type="fig"}, the LD flow signal shows a reperfusion peak flow before coming back to baseline. In addition to baseline values, the slope of reperfusion was calculated as described for StO~2~using linear adjustment (normal value ± standard deviation: baseline, 30.49 ± 21.30 TPU/seconds (local data) \[[@B35]\]; reperfusion slope, 48.62 ± 32.08 TPU/seconds). The relative reperfusion hyperemia was also calculated from baseline to peak (absolute TPU value). Data from reperfusion were expressed as absolute changes, as well as the percentage of variation from the preocclusion value.

![**Tissue hemoglobin oxygen saturation and laser Doppler measurement**. Example of a real tracing for tissue hemoglobin oxygen saturation (StO~2~) and laser Doppler measurements obtained before and during the occlusion test. TPU, tissue perfusion units.](cc8004-1){#F1}

Statistical analysis
--------------------

Data are summarized as the incidence and percentage for categorical variables. Quantitative variables are summarized as the median (25th to 75th percentiles). The reperfusion slope was dichotomized using the median value, which allowed fixing the threshold difference. The relationship between variables at day 1 (scores, macrohemodynamic, metabolic, NIRS and LD) and death within 28 days were tested by Wilcoxon test or Fisher exact test. Multivariate models were performed using multiple logistic regression. In model checking, we examined potential interactions and colinearity. Goodness of fit was evaluated using the method proposed by Le Cessie and Van Houwelingen. Models were compared using the log-likelihood ratio test. We used a linear mixed-effects model to analyze the pooled data from days 1, 2 and 3, and the relationships between StO~2~and SvO~2~, between the reperfusion slopes of StO~2~and LD, between StO~2~occlusion and reperfusion slopes, and between the StO~2~reperfusion slope and macrohemodynamic or metabolic data. The predictive value on outcome for the StO~2~reperfusion slope and SOFA score was calculated using a receiver operator characteristic curve with data obtained on day 1.

All tests were two-sided, at the 0.05 significance level. Analyses were carried out using the R statistical package \[[@B36]\].

Results
=======

Clinical characteristics
------------------------

Forty-three patients with septic shock were included in the study. Clinical characteristics are summarized in Table [1](#T1){ref-type="table"}. By definition, all patients had cardiovascular dysfunction and at least one other organ dysfunction at the time of recruitment. According to collegial decision, 11 patients (25.6%) received recombinant human activated protein C at the recommended dose rate and duration, 15 patients (34.8%) received low-dose hydrocortisone (50 mg four times daily) with no fludrocortisone, and three patients (7%) were treated with nitric oxide donors (molsidomine, 2 to 4 mg; Sanofi Aventis, Paris, France) \[[@B10]\]. The age of the 15 healthy volunteers ranged from 25 to 72 years.

###### 

Demographic and clinical characteristics of septic shock patients

  Characteristic                                        Value
  ----------------------------------------------------- ---------------
  Age (years)                                           70 (56 to 81)
  Sex (men)                                             25 (58.2)
  Sepsis origin                                         
   Abdominal                                            22 (51.2)
   Respiratory tract                                    11 (25.6)
   Skin/soft tissue                                     4 (9.3)
   Urinary tract                                        2 (4.7)
   Others                                               4 (9.3)
  Patients with recombinant human activated protein C   11 (25.6)
  Patients with corticoids                              15 (34.8)
  Patients with nitric oxide donors                     3 (7)
  Simplified Acute Physiology Score II                  57 (46 to 70)
  Sequential Organ Failure Assessment score:            
   Day 1                                                10 (8 to 13)
   Day 2                                                12 (9 to 14)
   Day 3                                                11 (7 to 14)
  Outcome (alive/dead)                                  28/15 (65/35)

Data are presented as median (25th to 75th percentiles) or *n*(%).

The actual mortality rate was 34.9% (15 patients), consistent with a group at high risk of death. Of these 15 nonsurviving patients, two (13.3%) received recombinant human activated protein C and four (26.6%) received hydrocortisone. There were no differences in age, sex, primary sites of infection or Simplified Acute Physiology Score II scores between survivors and nonsurvivors. The SOFA score on day 1, however, was higher in nonsurvivors compared with survivors (median 13 (12 to 16) vs. 9 (8 to 11), *P*= 0.001).

Among the hemodynamic parameters (Table [2](#T2){ref-type="table"}), only cardiac output was significantly different between survivors and nonsurvivors (6.8 (5.0 to 8.3) vs. 4.9 (4.1 to 6.9), *P*= 0.04). The lactate level was higher in nonsurvivors compared with survivors (median 6.8 (5.3 to 8.8) vs. 3.1 (2 to 4), *P*= 0.001), while the pH and base excess were lower in the former group of patients than in those who survived (7.2 (7.1 to 7.2) vs. 7.3 (7.2 to 7.4), *P*\< 0.001, and -12.3 (-14.25 to -10.4) vs. -7.3 (-10 to -3.8), *P*= 0.004, respectively) (Table [2](#T2){ref-type="table"}). The hemoglobin concentration showed no difference between both groups (*P*= 0.51) and was considered adequate.

###### 

Hemodynamic and metabolic data and severity scores at day 1

  Parameter                            Total group (n = 43)     Survivors (n = 28)   Nonsurvivors (n = 15)     *P*-value
  ------------------------------------ ------------------------ -------------------- ------------------------- -----------
  Heart rate (beats/minute)            108 (90 to 121)          108 (90 to 113)      110 (89 to 125)           NS
  Systolic arterial pressure (mmHg)    115 (100 to 121)         115 (103 to 120)     114 (88.5 to 127)         NS
  Diastolic arterial pressure (mmHg)   55 (47 to 62)            56 (49 to 62)        50 (45 to 62)             NS
  Cardiac output (l/minute)            5.9 (4.8 to 7.8)         6.8 (5.0 to 8.3)     4.9 (4.1 to 6.9)          0.04
  Right atrial pressure (mmHg)         11 (8 to 13)             11 (8 to 13)         12 (9 to 15)              NS
  pH                                   7.3 (7.2 to 7.3)         7.3 (7.2 to 7.4)     7.2 (7.1 to 7.2)          0.0003
  Base excess (mEq/l)                  -9.6 (-11.35 to -5.35)   -7.3 (-10 to -3.8)   -12.3 (-14.35 to -10.4)   0.004
  Lactate (mmol/l)                     4.1 (2.2 to 5.5)         3.1(2.0 to 4.0)      6.8 (5.3 to 8.8)          0.001
  Hemoglobin (g/dl)                    9.9 (9.0 to 11.2)        10 (9.2 to 11.1)     9.7 (8.6 to 11.2)         NS
  SAPS II                              57 (46 to 70)            56 (43 to 61)        65 (52 to 79)             0.08
  SOFA score                           10 (8 to 13)             9 (8 to 11)          13 (12 to 16)             0.001

Data are presented for patients with septic shock (total group), for survivors and for nonsurvivors as median (25th to 75th percentiles). NS, not significant; SAPS II, Simplified Acute Physiology Score II; SOFA, Sequential Organ Failure Assessment.

The evolution of patients surviving at least the first 3 days is described in Table [3](#T3){ref-type="table"} for the SOFA score, cardiovascular support, hemodynamic and metabolic items, StO~2~and LD data. One can note the rapid evolution of the hemodynamic parameters, norepinephrine dose, metabolic status and StO~2~parameters despite a relatively stable day-to-day SOFA score.

###### 

Evolution of SOFA score, dose of cardiovascular drugs, and systemic and microperfusion parameters in septic shock patients

  Parameter                            *n*   Day 1                    *n*   Day 2                    *n*   Day 3
  ------------------------------------ ----- ------------------------ ----- ------------------------ ----- ------------------------
  SOFA score                           43    10 (8 to 13)             39    12 (9 to 14)             35    11 (7 to 14)
  Norepinephrine (μg/kg/minute)        43    0.59 (0.32 to 0.85)      35    0.47 (0.25 to 0.80)      24    0.30 (0 to 0.56)
  Epinephrine (μg/kg/minute)           5     0.26 (0.22 to 0.37)      4     0.45 (0.17 to 0.78)      2     0.71 (0.62 to 0.80)
  Dobutamine (μg/kg/minute)            4     10 (7 to 11)             4     6 (2 to 10)              2     6.3 (5.7 to 7.0)
  Heart rate (beats/minute)            43    108 (90 to 121)          35    101 (80 to 108)          25    80 (74 to 102)
  Systolic arterial pressure (mmHg)    43    115 (100 to 121)         35    120 (111 to 130)         25    131 (109 to 147)
  Diastolic pressure (mmHg)            43    55 (47 to 62)            35    58 (52 to 64)            25    61 (52 to 68)
  Cardiac output (l/minute)            33    5.9 (4.8 to 7.8)         28    6.3 (5.0 to 7.2)         16    5.3 (4.9 to 7.5)
  Right atrial pressure (mmHg)         35    11 (8 to 13)             34    10 (7 to 14)             20    10 (6 to 11)
  pH                                   24    7.27 (7.22 to 7.33)      19    7.32 (7.28 to 7.39)      11    7.38 (7.35 to 7.41)
  Base excess (mEq/l)                  20    -9.6 (-11.4 to -5.4)     18    -4.8 (-8.0 to - 2.4)     11    -3.2 (-6.0 to 0.8)
  Lactate (mmol/l)                     23    4.14 (2.22 to 5.51)      19    2.30 (1.56 to 5.62)      7     3.00 (1.98 to 3.88)
  SvO~2~(%)                            39    75 (68 to 83)            34    74 (66 to 78)            22    70 (65 to 75)
  Hemoglobin (g/dl)                    43    9.9 (9.0 to 11.2)        38    9.5 (8.8 to 11.0)        33    9.6 (8.4 to 10.0)
  SpO~2~(%)                            43    99 (98 to 100)           38    99 (97 to 100)           33    99 (98 to 100)
  StO~2~(%)                            43    82 (75 to 88)            36    85 (78 to 92)            25    88 (80 to 92)
  StO~2~occlusion slope (%/second)     43    -0.31 (-0.47 to -0.24)   34    -0.48 (-0.65 to -0.31)   21    -0.42 (-0.62 to -0.34)
  StO~2~reperfusion slope (%/second)   43    2.79 (1.75 to 4.32)      34    4.37 (2.98 to 6.72)      21    5.15 (3.67 to 6.85)
  LD baseline flow (TPU)               15    2.74 (1.92 to 5.65)      13    5.30 (1.88 to 7.56)      9     6.57 (3.87 to 11.92)
  LD reperfusion slope (TPU/second)    15    1.16 (0.49 to 2.64)      13    1.98 (1.58 to 4.36)      9     3.38 (2.42 to 4.31)

Evolution at days 1, 2 and 3 of the Sequential Organ Failure Assessment (SOFA) score, the dose of vasopressor and inotropic drugs, and systemic (hemodynamic and metabolic) and microperfusion (near-infrared spectroscopy and laser Doppler (LD)) parameters in septic shock patients. Data are expressed as the median (25th to 75th percentiles). SvO~2~, central venous oxygen saturation (central venous + added 5% of saturation or arterial pulmonary blood gases); SpO~2~, pulse oxymetry; StO~2~, tissue hemoglobin oxygen saturation; TPU, tissue perfusion units.

Tissue hemoglobin oxygen saturation data
----------------------------------------

The baseline StO~2~was moderately lower in septic shock patients compared with healthy volunteers (82% (75 to 88) vs. 89% (85 to 92), *P*= 0.04). In addition, the reperfusion slope was lower in septic shock patients compared with volunteers (median 2.79%/second (1.75 to 4.32) vs. 9.35%/second (8.32 to 11.57), *P*\< 0.0001) (Figure [2a, b](#F2){ref-type="fig"}), with no difference for occlusion slopes (*P*= 0.11).

![**Baseline tissue hemoglobin oxygen saturation and the reperfusion slope**. **(a)**Box plot for baseline tissue hemoglobin oxygen saturation (StO~2~) in healthy volunteers compared with that for septic shock patients on day 1. **(b)**Box plot for reperfusion slope in healthy subjects compared with that for septic shock patients on day 1.](cc8004-2){#F2}

Looking at the survivors versus the nonsurvivors, the two groups had similar baseline StO~2~values (82% (75 to 87) vs. 82% (73 to 92), *P*= 0.86) and occlusion slopes (-0.35%/second (-0.54 to -0.24) vs. -0.3%/second (-0.37 to -0.25), *P*= 0.36) (Table [3](#T3){ref-type="table"}). The reperfusion slopes were significantly lower in nonsurvivors compared with survivors (median 1.88%/second (1.56 to 2.76) vs. 3.98%/second (2.25 to 6.04), *P*= 0.003) on day 1 (Table [3](#T3){ref-type="table"}). The difference for the reperfusion slope between the survivors and nonsurvivors related to intensive care unit death (odds ratio = 0.46, 95% confidence interval = 0.26 to 0.83).

No difference was observed in the gradients between SpO~2~and StO~2~or between StO~2~and SvO~2~in survivors and non-survivors (Table [3](#T3){ref-type="table"} and Table [4](#T4){ref-type="table"}). There was also no correlation between SpO~2~and StO~2~(data not shown), nor between StO~2~and SvO~2~(*P*= 0.86) (Figure [3](#F3){ref-type="fig"}).

###### 

Tissue hemoglobin oxygen saturation parameters measured at day 1

  Parameter                      Total group (n = 43)     Survivors (n = 28)       Nonsurvivors (n = 15)   *P*-value
  ------------------------------ ------------------------ ------------------------ ----------------------- -----------
  SpO~2~(%)                      99 (98 to 100)           99 (97 to 100)           100 (99 to 100)         0.18
  StO~2~(%)                      82 (75 to 88)            82 (75 to 87)            82 (73 to 92)           0.86
  SvO~2~(%)                      75 (68 to 83)            76 (70 to 84)            73 (68 to 77)           0.22
  ΔSpO~2~- StO~2~(%)             17 (9 to 24)             16 (9 to 22)             18 (7.5 to 25)          0.96
  ΔStO~2~- SvO~2~(%)             5 (-7 to 19)             4.5 (-3 to 18.1)         10 (-10.3 to 20.5)      0.61
  ΔStO~2~- SvO~2~/StO~2~         0.06 (-0.1 to 0.2)       0.05 (-0.04 to 0.2)      0.14 (-0.1 to 0.2)      0.69
  ΔStO~2~- SvO~2~/SvO~2~         0.08 (-0.03 to 0.3)      0.05 (-0.03 to 0.3)      0.18 (0 to 0.3)         0.50
  Occlusion slope (%/second)     -0.31 (-0.47 to -0.24)   -0.35 (-0.54 to -0.24)   -0.3 (-0.37 to -0.25)   0.36
  Reperfusion slope (%/second)   2.79 (1.75 to 4.32)      3.98 (2.25 to 6.04)      1.88 (1.56 to 2.76)     0.003

Tissue hemoglobin oxygen saturation (StO~2~) parameters measured on day 1 in patients with septic shock (total group), in survivors and in nonsurvivors. Data are presented as median (25th to 75th percentiles). SpO~2~, pulse oxymetry; SvO~2~, central venous oxygen saturation (included mixed venous oxygen saturation and superior vena cava oxygen saturation + 5%); Δ, gradient between stated parameters.

![**Correlation between central venous oxygen saturation and tissue hemoglobin oxygen saturation**. Correlation between central venous oxygen saturation (SvO~2~) and tissue hemoglobin oxygen saturation (StO~2~) obtained during the first day of septic shock.](cc8004-3){#F3}

Figure [4](#F4){ref-type="fig"} shows the significant correlations observed with the reperfusion slope, which might clarify the determinants of such a parameter in septic shock. Among the hemodynamic and metabolic parameters evaluated on days 1, 2, and 3, we observed a positive correlation between the StO~2~reperfusion slope and cardiac output (*P*= 0.01) and a negative correlation between the StO~2~reperfusion slope and arterial lactate (*P*= 0.04). The occlusion and the reperfusion slopes correlated well: the faster the StO~2~decay during the stagnant ischemia, the faster the reperfusion slope (*P*\< 0.0001). No correlation between the reperfusion slope and blood pressure, pH or base excess was observed.

![**Correlation between hemodynamic and metabolic parameters and occlusion and reperfusion slopes**. **(a)**Correlation between tissue hemoglobin oxygen saturation (StO~2~) occlusion and reperfusion slopes for 98 measurements performed on 43 patients (day 1, 43 measurements; day 2, 34 measurements; day 3, 21 measurements) during the first 3 days of septic shock. **(b)**Correlation between reperfusion slope and cardiac output (CO) obtained for 77 measurements, corresponding to 33 patients on day 1, 28 patients on day 2, and 16 patients on day 3. **(c)**Correlation between lactate plasma concentration and reperfusion slope (48 measurements), corresponding to 23 patients measured on day 1, 18 patients on day 2, and seven patients on day 3. **(d)**Correlation between the reperfusion slope obtained with laser Doppler and the one obtained with StO~2~during the simultaneous occlusion tests: 37 measurements were obtained, on 15 patients on day 1, 13 patients on day 2, and nine patients on day 3. TPU, tissue perfusion units.](cc8004-4){#F4}

The predictive value on outcome of the reperfusion slope was calculated using a receiver operator characteristic curve. The receiver operator characteristic curve showed the StO~2~reperfusion slope as a good outcome predictor (area under the curve = 0.77). The best cut-off value was 2.83%/second, with a sensitivity of 80% and a specificity of 67%. In addition, using a multivariable model, the StO~2~reperfusion slope added a significant prognostic value both to the SOFA score (*P*= 0.037) (Figure [5](#F5){ref-type="fig"}) and to the Simplified Acute Physiology Score II (*P*= 0.015) (data not shown).

![**Predictive value on outcome**. Area under the curve (AUC) for the multivariate model using each determinant alone or in combination (solid curve). Se, sensitivity; SOFA, Sequential Organ Failure Assessment; Sp, specificity.](cc8004-5){#F5}

Laser Doppler data
------------------

Fifteen (34.8%) out of the 43 septic shock patients were also evaluated with the skin LD technique. Values obtained for the total group were: baseline, 2.74 TPU (1.92 to 5.65) (normal values ± standard deviation: 30.49 ± 21.30); peak value during the hyperemic phase, 6.67 TPU (5.02 to 9.3); peak value-baseline difference, 3.62 TPU (1.88 to 4.58); reper-fusion slope, 1.16 TPU/second (0.49 to 2.64) (normal values ± standard deviation: 48.62 ± 32.08). There were no significant differences in these parameters between survivors and nonsurvivors (data not shown). The LD reperfusion slope tended to correlate with the StO~2~reperfusion slope, but did not reach statistical significance (*P*= 0.08) (Figure [4d](#F4){ref-type="fig"}).

Discussion
==========

This prospective, observational study follows the recently published study by Creteur and colleagues on severe sepsis and septic shock using the same device \[[@B22]\]. The primary new inputs of our study design are the selection of a very homogeneous population (that is, only septic shock patients having at least one additional organ failure), two techniques for microperfusion assessment (StO~2~and skin LD), a day 1 evaluation of the predictive value of the reperfusion slope with a clear difference in median between survivors and non-survivors, and an investigation of the potential determinants of the reperfusion slope (systemic hemodynamic and metabolic parameters such as lactate and the occlusion slope). Our StO~2~parameters in septic shock confirm the observations made by Creteur and colleagues in septic shock: the muscle baseline StO~2~is slightly lower in septic shock patients than in healthy controls; and only the StO~2~reperfusion slope and not the occlusion slope is slower in septic shock than in healthy controls. In addition, the StO~2~reperfusion slope was lower at day 1 in nonsurvivors than in survivors and predicted outcome within 28 days. The LD data, although abnormal, did not correlate well with StO~2~parameters. The link between systemic hemodynamic or metabolic parameters with the StO~2~reperfusion slope suggests an impact on tissue micro-oxygenation, even if their respective role cannot be precisely determined.

The development of non-invasive bedside tools to assess microperfusion alterations has prompted clinicians to look at the previously recognized and demonstrated microcirculation impairment occurring in severe sepsis or septic shock \[[@B3],[@B5],[@B37]\]. Among these tools, some image microvessel flowing conditions, such as sublingual orthogonal polarisation spectral (OPS) or sidestream dark field (SDF) \[[@B5],[@B38]\], some evaluate local tissue perfusion as carbon dioxide tonometry \[[@B39]\], some measure local tissue microvessel blood flow such as LD \[[@B35]\] and, finally, some assess tissue micro-oxygenation by NIRS \[[@B24]\].

NIRS uses the differential absorption properties of oxygenated and deoxygenated hemoglobin to evaluate oxygenation of tissues such as skeletal muscle. Near-infrared light (680 to 800 nm) easily crosses biological tissues, which have a low absorption power, and is absorbed only by hemoglobin, myoglobin, and oxidized cytochrome, with the contribution of the latter two to the light attenuation signal being very small \[[@B30]\]. NIRS has several advantages since, in addition to being non-invasive, it is easy to use, does not require expertise to obtain adequate results, and is a continuous method providing numbers and continuous trends. NIRS has been used in different clinical conditions such as severe trauma \[[@B13]-[@B17]\], hemorrhagic shock \[[@B40],[@B41]\], cardiogenic shock or severe cardiac failure \[[@B42]\] and septic shock \[[@B18]-[@B22]\]. The limitations of NIRS should also be mentioned. Since this technique does not measure microvessel blood flow or capillary density, it has a signal ambiguity related to illumination of venous, capillary and arteriolar vessels. Several parameters can be obtained from NIRS numerical data, as demonstrated by De Blasi and colleagues \[[@B24]\]. Among these, the simplest parameters and the most understandable by the clinician are the baseline StO~2~and the functional regional circulatory test (VOT) response \[[@B24]\]. The VOT was developed in septic shock because baseline StO~2~did not clearly differ from controls \[[@B14]-[@B18]\], contrary to hemorrhagic trauma situations \[[@B40],[@B41]\].

The initial studies on sepsis, severe sepsis or septic shock \[[@B14]-[@B17]\] have reported small differences in baseline StO~2~compared with healthy controls. We confirm in the present study such a small, though significant, difference. Since the StO~2~value at the thenar eminence is higher than the central SvO~2~and lower than SpO~2~, we analyzed the potential meaning of the gradients between and these other StO~2~oxygen saturations. Gradients did not differ between survivors and nonsurvivors, but, since their evolution was not studied, further investigation might be important to evaluate a potential impact on outcome or severity. We also found no correlation between SpO~2~and StO~2~or between StO~2~and SvO~2~.

Whether ScvO~2~is an adequate surrogate for SvO~2~has been a matter of continuous debate. We pooled ScvO~2~+ 5% and SvO~2~values for the analysis. Both parameters are low in early septic shock and have been shown to be useful to detect and treat global tissue hypoxia during the resuscitation period. Although the absolute values of ScvO~2~and SvO~2~differ, studies have consistently shown close trends and tracking between the two in several hemodynamic conditions. The presence of a low ScvO~2~indicates even lower SvO~2~, the difference being (on average) approximately 5%. If joining both sources might have induced a small inaccuracy in the step-by-step numerical StO~2~-SvO~2~gradient, therefore, this does not alter the fact that there was no correlation between them. Many studies have also reported the time variations of StO~2~slopes during the VOT, even when performed with different protocols - time to reach a low threshold of 40% \[[@B15],[@B19]\] or a duration of 3 to 5 minutes of occlusion \[[@B18],[@B20]-[@B22]\]. The present study confirms the previous results for baseline StO~2~and for StO~2~occlusion and reperfusion slopes \[[@B20]-[@B22]\]. Clearly, the StO~2~reperfusion slope appears the most discriminating parameter for sepsis severity, as previously mentioned \[[@B22]\]. The reperfusion slope was slower in septic shock than in severe sepsis and was comparable with the values we obtained.

In addition, we observed for the first time that the StO~2~reperfusion slope within the first 24 hours of septic shock was different between survivors and nonsurvivors at 28 days in this homogeneous population. Considering this difference, we decided to look at the predictive value for outcome of this parameter alone, in comparison or in combination with the SOFA score. Using multivariate analysis, we observed a good predictive value of the StO~2~reperfusion slope, although not superior to the day 1 SOFA score. Unlike the SOFA score, however, the StO~2~reperfusion slope can be obtained several times a day. Taking into account the number of StO~2~values measured during the reperfusion time (one value every 3 seconds), only five or six values can be obtained. This small number of values may induce error in the slope calculation, especially if the tracing is not linear. Consequently, we decided to apply the linear adjustment model and check the *R*^2^value. It was only when *R*^2^was \>0.90 that we took the linear slope value. Nonlinear reperfusion tracings were observed in 20% of the performed VOTs. The recent development of the incorporated software in the device has integrated this calculation online.

Although performed on both severe sepsis patients and septic shock patients, the reported area under the receiver operating characteristic curve for the StO~2~reperfusion slope outcome predictive value \[[@B22]\] was comparable with the one we obtained in septic shock patients (0.797 vs. 0.77, respectively), suggesting a good reproducibility. The calculated threshold for the reperfusion slope (2.83%/second) was also very similar to the one previously reported (2.55%/second) \[[@B22]\], with a sensitivity of 80% and a specificity of 67%. This area under the curve was also similar to that obtained with day 1 SOFA values (0.79). Combining the StO~2~reperfusion slope and SOFA score predictive values showed a significant amelioration of predictive value, raising the area under the curve to 0.85.

As the most discriminating parameter for outcome and severity \[[@B22]\], the determinants of the StO~2~reperfusion slope require discussion. The relationship with macrohemo-dynamics is the first line of investigation. We observed a significant relation only between cardiac output and the StO~2~reperfusion slope, which has never been reported before in septic shock - such a relation had only been shown in severe cardiac failure \[[@B42]\]. Although weak (*P*\< 0.01), the relation indicates that systemic flow influences thenar StO~2~. Classically in septic shock, adequacy of perfusion for oxygen demand is assessed by the blood lactate level. In the present study, the lactate level logically negatively correlated with the StO~2~reperfusion slope, which was slower when lactate levels were higher. This suggests that NIRS can detect poor tissue oxygenation or bad vascular reserve that results in lactate elevation during septic shock. Taking these relationships (cardiac output and lactate) into account, it is reasonable to think that poor perfusion at the systemic level influences an abnormal StO~2~reperfusion slope. Separating the hyperproduction of lactate from a stagnant elevation of lactate level is not possible due to poor washout.

The second line of determinants may relate to local perfusion, which may be impaired because of low microvessel blood flow or the low density of perfused microvessels. In addition, changes in vascular blood compartmentalization between venules, capillaries and small arteries may also influence the StO~2~measurement. Despite limitations, initial investigation of these determinants was made measuring forearm skin blood flow using LD at baseline and during the same VOT performed for StO~2~. In this population of septic shock patients, the LD baseline and the VOT response were abnormal in comparison with healthy volunteers. The abnormal hyperemic response has been attributed to an abnormal capability of the vessels to dilate after ischemia, mediated by a deficit in vasodilatating substances such as prostaglandins or nitric oxide \[[@B2],[@B6],[@B9],[@B43]\]. The nearly significant (*P*= 0.08) correlation between LD and the StO~2~reperfusion slopes is important, since the relation between skin LD and StO~2~parameters has not been reported previously. The slower the StO~2~slope, the slower the reperfusion slope of the LD. The combination of a small number of patients and the differences between skin blood flow and skeletal muscle flow regulations may explain the weakness of the correlation \[[@B33]\]. This suggests a potential impact of microvessel blood flow in the observed abnormal StO~2~reperfusion slope.

The observed strong correlation between StO~2~occlusion and reperfusion slopes needs further discussion; that is, the deeper the occlusion slope, the faster the reperfusion slope. The explanation for such an observation can only be speculated on the basis of the previous demonstration of the determinants of these slopes \[[@B15],[@B19]-[@B22],[@B24]\]. The StO~2~occlusion slope seems to relate primarily to muscle oxygen consumption. It was shown that the higher the muscle oxygen consumption, the faster will be the StO~2~decay over time \[[@B18]-[@B21],[@B24]\]. In our septic shock population, the correlation may depend on the importance of muscle ischemia created by the VOT. Occurring faster after occlusion, the ischemia will be longer - which might induce a more pronounced muscle ischemia, with the release of more vasodilating substances. This aspect requires further investigation for clarification.

Conclusion
==========

In the present study, the StO~2~reperfusion slope is an early predictive value for outcome in septic shock patients. Its performance improves when combined with well-known severity scores. Some relations between macroperfusion and microperfusion influence the measured StO~2~variables. When StO~2~baseline values indicate adequate perfusion, but microcirculatory dysfunction is suspected, the use of the VOT seems promising for a functional microperfusion evaluation. Because of the intricate determinants of microperfusion, a multimodal assessment to better characterize microperfusion is needed. Further studies are warranted to validate the NIRS measurements using a different probe (15 mm) working more superficially in the thenar eminence than the probe used initially (25 mm).
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